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BACKGROUND
Patients at high risk for bleeding who undergo percutaneous coronary intervention 
(PCI) often receive bare-metal stents followed by 1 month of dual antiplatelet 
therapy. We studied a polymer-free and carrier-free drug-coated stent that transfers 
umirolimus (also known as biolimus A9), a highly lipophilic sirolimus analogue, 
into the vessel wall over a period of 1 month.
METHODS
In a randomized, double-blind trial, we compared the drug-coated stent with a 
very similar bare-metal stent in patients with a high risk of bleeding who under-
went PCI. All patients received 1 month of dual antiplatelet therapy. The primary 
safety end point, tested for both noninferiority and superiority, was a composite 
of cardiac death, myocardial infarction, or stent thrombosis. The primary efficacy 
end point was clinically driven target-lesion revascularization.
RESULTS
We enrolled 2466 patients. At 390 days, the primary safety end point had occurred 
in 112 patients (9.4%) in the drug-coated–stent group and in 154 patients (12.9%) 
in the bare-metal–stent group (risk difference, −3.6 percentage points; 95% confi-
dence interval [CI], −6.1 to −1.0; hazard ratio, 0.71; 95% CI, 0.56 to 0.91; P<0.001 
for noninferiority and P = 0.005 for superiority). During the same time period, 
clinically driven target-lesion revascularization was needed in 59 patients (5.1%) in 
the drug-coated–stent group and in 113 patients (9.8%) in the bare-metal–stent 
group (risk difference, −4.8 percentage points; 95% CI, −6.9 to −2.6; hazard ratio, 
0.50; 95% CI, 0.37 to 0.69; P<0.001).
CONCLUSIONS
Among patients at high risk for bleeding who underwent PCI, a polymer-free 
umirolimus-coated stent was superior to a bare-metal stent with respect to the 
primary safety and efficacy end points when used with a 1-month course of dual 
antiplatelet therapy. (Funded by Biosensors Europe; LEADERS FREE ClinicalTrials 
.gov number, NCT01623180.)
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A mong patients undergoing percu-taneous coronary intervention (PCI), it is estimated that 15% or more are at high 
risk for bleeding.1,2 Such patients are usually 
excluded from trials of stents and adjunctive 
therapy, and the default management of their 
care, supported by current guidelines,3,4 favors 
the use of either a second-generation drug-elut-
ing stent with a shortened course of dual anti-
platelet therapy or a bare-metal stent followed by 
1 month of dual antiplatelet therapy. The latter 
strategy, driven by the need to minimize the risk 
of bleeding, is associated with a higher risk of 
restenosis and reintervention than that observed 
with the use of a drug-eluting stent.5
A polymer-free and carrier-free drug-coated 
stent, the BioFreedom stent (Biosensors Europe), 
has been developed that transfers umirolimus 
(also known as biolimus A9), a highly lipophilic 
sirolimus analogue, into the vessel wall over a 
period of 1 month. In a preclinical study, the 
umirolimus-coated stent showed less neointimal 
proliferation and inflammation at 180 days than 
did a sirolimus-eluting stent.6 In a first-in-human 
evaluation, the umirolimus-coated stent was 
noninferior to a paclitaxel-eluting stent with re-
spect to in-stent late lumen loss at 12 months.7 
The Prospective Randomized Comparison of the 
BioFreedom Biolimus A9 Drug-Coated Stent ver-
sus the Gazelle Bare-Metal Stent in Patients at 
High Bleeding Risk (LEADERS FREE) trial was 
designed to evaluate the efficacy and safety of 
the polymer-free umirolimus-coated stent as com-
pared with a bare-metal stent in patients with 
increased bleeding risk, with a 1-month regimen 
of dual antiplatelet therapy in both groups.
Me thods
Study Design and Organization
The LEADERS FREE trial is an ongoing ran-
domized, double-blind clinical trial conducted 
at 68 sites in 20 countries on 4 continents (see 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The study 
design has been described previously.2
The trial was sponsored by Biosensors Europe 
(Morges, Switzerland). The sponsor approved the 
trial protocol, which was developed by the execu-
tive committee and is available at NEJM.org. The 
sponsor had no role in site monitoring, the col-
lection, storage, or analysis of the data, or the 
decision to submit the manuscript for publica-
tion. Two members of the executive committee 
were employees of the sponsor and contributed 
to the writing of the manuscript. No agreement 
regarding data confidentiality was made be-
tween the sponsor and the executive committee.
The study was conducted in accordance with 
the trial protocol by Centre Européen de Recher-
che Cardiovasculaire (CERC; Massy, France), an 
independent research organization paid by the 
sponsor. The institutional review board at each 
site approved the study. The first six authors and 
last three authors wrote the manuscript, had full 
access to the data, and vouch for the complete-
ness and accuracy of data and analyses and for 
the fidelity of this report to the trial protocol.
Study Population
Eligible patients had coronary artery disease with 
a clinical indication for PCI. In addition, partici-
pants were required to meet one or more of the 
criteria listed in Table 1. These criteria were cho-
sen to define a population of patients who had 
increased bleeding risk or who were otherwise 
considered by the investigator to be candidates 
for implantation of a bare-metal stent instead of 
a drug-eluting stent, owing to the perceived need 
to terminate dual antiplatelet therapy at 1 month. 
Detailed inclusion and exclusion criteria are listed 
in the Supplementary Appendix. All patients pro-
vided written informed consent.
Study Procedures
Patients were randomly assigned in a 1:1 ratio to 
undergo PCI with the BioFreedom polymer-free 
umirolimus-coated stent or a similar bare-metal 
stent (the Gazelle stent, Biosensors Interven-
tional Technologies, Singapore). Details of the 
design of both stents are provided in the Supple-
mentary Appendix. Randomization was performed 
with the use of either a Web-based system or a 
telephone interactive voice-response system (both 
from Merge Healthcare) in blocks of 16 with no 
stratification. The patients, investigators, and 
members of the clinical-events committee and 
the executive committee were unaware of the 
study-group assignments.
Patients were enrolled after the guidewire had 
crossed the first target lesion, and PCI was per-
formed according to standard techniques. Vascu-
lar access, periprocedural antithrombotic regimen, 
and lesion preparation were left to the operator’s 
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Variable
Drug-Coated Stent 
(N = 1221)
Bare-Metal Stent 
(N = 1211)
Baseline characteristics
Age — yr 75.7±9.4 75.7±9.3
Female sex — no. (%) 364 (29.8) 374 (30.9)
Body-mass index† 27.5±4.8 27.2±4.6
Diabetes — no./total no. (%) 414/1217 (34.0) 391/1210 (32.3)
Hypertension — no./total no. (%) 952/1219 (78.1) 961/1208 (79.6)
Hypercholesterolemia — no./total no. (%) 742/1197 (62.0) 746/1189 (62.7)
STEMI — no. (%) 57 (4.7) 48 (4.0)
NSTEMI — no. (%) 273 (22.4) 281 (23.2)
Unstable angina — no. (%) 177 (14.5) 193 (15.9)
Stable CAD — no. (%) 714 (58.5) 689 (56.9)
Multivessel disease — no./total no. (%) 755/1201 (62.9) 738/1198 (61.6)
Previous myocardial infarction — no./total no. (%) 237/1211 (19.6) 258/1203 (21.4)
Previous PCI — no./total no. (%) 270/1215 (22.2) 265/1208 (21.9)
Previous CABG — no./total no. (%) 115/1217 (9.4) 122/1209 (10.1)
Congestive heart failure — no./total no. (%) 175/1212 (14.4) 150/1211 (12.4)
Atrial fibrillation — no./total no. (%) 424/1215 (34.9) 418/1209 (34.6)
Previous stroke — no./total no. (%) 132/1212 (10.9) 110/1208 (9.1)
Peripheral vascular disease — no./total no. (%) 190/1208 (15.7) 190/1201 (15.8)
Chronic obstructive lung disease — no./total no. (%) 131/1207 (10.9) 141/1202 (11.7)
CRUSADE score‡ 34.1±0.4 34.6±0.4
Inclusion criteria — no. (%)§
Age ≥75 yr 788 (64.5) 776 (64.1)
Oral anticoagulation planned to continue after PCI 448 (36.7) 431 (35.6)
Hemoglobin <11 g/liter or transfusion within 4 wk before random-
ization
185 (15.2) 194 (16.0)
Platelet count <100,000/mm3 20 (1.6) 18 (1.5)
Hospital admission for bleeding in previous 12 mo 46 (3.8) 33 (2.7)
Stroke in previous 12 mo 15 (1.2) 24 (2.0)
Previous intracerebral hemorrhage 14 (1.1) 19 (1.6)
Severe chronic liver disease 11 (0.9) 10 (0.8)
Creatinine clearance <40 ml/min 219 (17.9) 245 (20.2)
Cancer in previous 3 yr¶ 119 (9.7) 120 (9.9)
Planned major surgery in next 12 mo 187 (15.3) 211 (17.4)
Glucocorticoids or NSAID planned for >30 days after PCI 38 (3.1) 34 (2.8)
Expected nonadherence to >30 days of dual antiplatelet therapy 41 (3.4) 47 (3.9)
*  Plus–minus values are means ±SD. There were no significant differences (P<0.05) between the two groups in any of 
the baseline characteristics. CABG denotes coronary-artery bypass grafting, CAD coronary artery disease, NSAID non-
steroidal antiinflammatory drug, NSTEMI non–ST-segment elevation myocardial infarction, PCI percutaneous coronary 
intervention, and STEMI ST-segment elevation myocardial infarction.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Scores on the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with 
Early Implementation of the American College of Cardiology/American Heart Association Guidelines) bleeding risk 
scale8 range from 1 to 100, with higher scores indicating a higher risk of major bleeding.
§  These criteria were not mutually exclusive.
¶  Cancer excluded skin cancer.
Table 1. Baseline Patient Characteristics and Inclusion Criteria.*
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preference. All target lesions were treated with 
at least one study stent. Staged procedures were 
permitted within 1 week after the index procedure; 
all the stents used were of the assigned type.
The protocol mandated that all patients re-
ceive both aspirin (75 to 250 mg once daily) and 
a P2Y12 inhibitor (with clopidogrel, 75 to 150 mg 
once daily, being the preferred agent) for 30 days, 
followed by a single antiplatelet agent thereafter 
(aspirin preferred). Patients who were discharged 
while receiving a vitamin K antagonist could re-
ceive either triple therapy or the vitamin K antago-
nist plus clopidogrel (without aspirin) during the 
first 30 days.9
A patient follow-up visit was performed at the 
study center at 30 days (time window, 23 to 37 
days), when the change from dual antiplatelet 
therapy to single antiplatelet therapy was pre-
scribed, and again at 360 days. Further contacts, 
either on site or by telephone, were made at 60, 
120, and 720 days. Ischemia testing and angio-
graphic evaluation during follow-up were not 
mandated by the protocol and were left to the 
discretion of the investigator.
Study End Points
The primary safety end point was the cumulative 
incidence of a composite of cardiac death, myo-
cardial infarction, or definite or probable stent 
thrombosis at 390 days. The primary efficacy end 
point was the incidence of clinically driven target-
lesion revascularization at 390 days. Other end 
points included bleeding, target-vessel revascular-
ization, and indexes of technical procedural suc-
cess. Primary end-point events and bleeding events 
were recorded for up to 390 days in order to cap-
ture any events occurring soon after (and as a 
consequence of) the planned 1-year visit.
Myocardial infarction was defined according to 
the third universal definition of myocardial infarc-
tion,10 stent thrombosis according to the Academic 
Research Consortium definitions,11 and bleeding 
according to the Bleeding Academic Research Con-
sortium (BARC) definitions.12 Clinically driven 
target-lesion revascularization was defined as PCI 
or surgery either for an operator-defined restenosis 
in the treated lesion together with angina symp-
toms or documented ischemia or for a core-labo-
ratory–defined restenosis of greater than 70% of 
the artery diameter when neither symptoms nor 
ischemia were present (see the Supplementary 
Appendix for detailed end-point definitions).
Data verification and core-laboratory angio-
graphic assessment of all cases of stent throm-
bosis and revascularization were performed by 
CERC. An independent clinical-events commit-
tee adjudicated all components of both primary 
end points and all bleeding events.
Statistical Analysis
The composite primary safety end point was 
evaluated with the use of a noninferiority analy-
sis. We predicted a 1-year incidence of 8% for 
this end point in the bare-metal–stent group. 
Noninferiority was to be declared if the upper 
limit of the one-sided 97.5% confidence interval 
of the difference in event rates between the two 
groups at 1 year was less than 3.2 percentage 
points. After allowing for a rate of loss to fol-
low-up of up to 5% and for the censoring of data 
from up to 3% of patients owing to death from 
noncardiac causes, we determined that a sample 
size of 1228 patients per group would provide 
more than 80% power to detect noninferiority. If 
noninferiority were shown, the composite safety 
end point would then be tested for superiority.
For the primary efficacy end point of clini-
cally driven target-lesion revascularization, we 
predicted an event rate of 10% at 1 year in the 
bare-metal–stent group. Using a two-sided type 
I error rate of 5% and allowing for a rate of loss 
to follow-up of up to 8%, we determined that 
1228 patients per group would provide more 
than 80% power to detect an absolute difference 
of 3.3 percentage points in the rate of clinically 
driven target-lesion revascularization between 
study groups.
All primary results are based on a modified 
intention-to-treat analysis (i.e., after the exclu-
sion of 34 patients who were mistakenly as-
signed before coronary angiography and were 
found not to have a suitable lesion for PCI). 
Secondary as-treated analyses were performed 
after the exclusion of a further 31 patients who 
received a nonstudy stent and the reassignment 
of the 9 patients who mistakenly received a 
study stent from the other group.
Time-to-event analyses were performed with 
the use of the Kaplan–Meier method, and the 
two stents were compared with the use of the 
log-rank test for the time to the first event after 
randomization. Risk differences at 390 days and 
their 95% confidence intervals were calculated 
with the use of these Kaplan–Meier estimates 
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and their standard errors. Proportional-hazards 
models were used to estimate hazard ratios and 
their 95% confidence intervals. The consistency 
of treatment effects across prespecified sub-
groups was assessed with the use of proportion-
al-hazards models with tests for interaction. All 
P values and 95% confidence intervals were two-
sided except for the noninferiority analysis for 
the composite primary safety end point, for which 
a one-sided 97.5% confidence interval was used. 
Analyses were performed with Stata software, 
version 13.1 (StataCorp).
R esult s
Study Population and Procedures
A total of 2466 patients underwent randomiza-
tion (1239 were assigned to the polymer-free 
umirolimus-coated stent and 1227 were assigned 
to the bare-metal stent) from December 2012 
through May 2014. Of the 2432 patients who 
underwent PCI, 2385 (98.1%) were followed until 
death or 390 days (Fig. 1). The patient population 
was characterized by advanced age and major 
coexisting conditions indicative of increased bleed-
ing risk. Patients had a mean of 1.7 inclusion 
criteria, and the two groups were well balanced 
with respect to baseline characteristics (Table 1).
A total of 60.7% of procedures in the drug-
coated–stent group and 58.7% in the bare-metal–
stent group were performed through a radial 
access, and 4.5% and 5.9% of procedures in the 
respective groups were staged. A total of 21.8% 
of procedures in the drug-coated–stent group and 
21.4% in the bare-metal–stent group involved mul-
tivessel revascularization (Table S1 in the Supple-
mentary Appendix). Dual antiplatelet therapy was 
being used by 96.5% and 96.9% of patients in 
the respective groups at discharge, by 95.2% and 
94.7% at 23 days, and by 9.1% and 9.8% at 37 
days (Table S2 in the Supplementary Appendix).
Primary End Points
At 390 days, the primary safety end point (a com-
posite of cardiac death, myocardial infarction, 
or stent thrombosis) had occurred in 112 pa-
tients (9.4%) in the drug-coated–stent group and 
in 154 patients (12.9%) in the bare-metal–stent 
Figure 1. Randomization, Treatment, and Follow-up of the Patients.
PCI denotes percutaneous coronary intervention.
2466 Patients underwent randomization
1239 Were assigned to drug-coated stent 1227 Were assigned to bare-metal stent
18 Did not undergo PCI
13 (1.1%) Withdrew before
12-mo visit
12 (1.0%) Were lost to
follow-up
16 Did not undergo PCI
1221 Were included in the modified
intention-to-treat analysis
7 Received bare-metal stent
2 Received bare-metal stent and
drug-coated stent
17 Received a nonstudy stent
1211 Were included in the modified
intention-to-treat analysis
2 Received drug-coated stent
14 Received a nonstudy stent
10 (0.8%) Withdrew before
12-mo visit
12 (1.0%) Were lost to 
follow-up
1189 (98.2%) Completed 12-mo visit
or died
1196 (98.0%) Completed 12-mo visit
or died
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group (estimated absolute risk difference, −3.6 
percentage points; 95% confidence interval [CI], 
−6.1 to −1.0; P<0.001 for noninferiority) (Table 2). 
A preplanned superiority analysis was then per-
formed for the primary safety end point (hazard 
ratio, 0.71; 95% CI, 0.56 to 0.91; P = 0.005 for 
End Point
Drug-Coated 
Stent 
(N = 1221)
Bare-Metal 
Stent 
(N = 1211)
Hazard Ratio 
(95% CI) P Value
no. of events (% of patients)
Primary safety end point: cardiac death, myocardi-
al infarction, or stent thrombosis
112 (9.4) 154 (12.9) 0.71 (0.56–0.91) 0.005†
Primary efficacy end point: clinically driven TLR 59 (5.1) 113 (9.8) 0.50 (0.37–0.69) <0.001
Death
From any cause 97 (8.0) 108 (9.0) 0.89 (0.67–1.17) 0.39
From cardiac causes 50 (4.2) 63 (5.3) 0.78 (0.54–1.14) 0.20
Myocardial infarction‡
Any 72 (6.1) 104 (8.9) 0.68 (0.50–0.91) 0.01
Q-wave infarction 6 (0.5) 7 (0.6) 0.85 (0.29–2.53) 0.77
Non–Q-wave infarction 57 (4.8) 80 (6.9) 0.70 (0.50–0.98) 0.04
Undetermined type 10 (0.8) 25 (2.1) 0.39 (0.19–0.82) 0.01
Stent thrombosis‡
Definite or probable 24 (2.0) 26 (2.2) 0.91 (0.53–1.59) 0.75
Definite 16 (1.3) 17 (1.4) 0.93 (0.47–1.84) 0.84
Probable 8 (0.7) 9 (0.8) 0.88 (0.34–2.28) 0.80
Possible 25 (2.2) 27 (2.3) 0.91 (0.53–1.57) 0.74
Acute 5 (0.4) 5 (0.4) 0.99 (0.29–3.43) 0.99
Subacute 7 (0.6) 10 (0.8) 0.69 (0.26–1.82) 0.45
Early: acute + subacute 12 (1.0) 15 (1.2) 0.79 (0.37–1.70) 0.55
Late 13 (1.1) 11 (1.0) 1.17 (0.52–2.61) 0.70
Revascularization
Urgent TLR 39 (3.3) 67 (5.8) 0.57 (0.38–0.84) 0.004
Any TLR 60 (5.1) 115 (10.0) 0.50 (0.37–0.68) <0.001
Clinically driven TVR 66 (5.7) 121 (10.5) 0.52 (0.39–0.71) <0.001
Any TVR 67 (5.8) 125 (10.9) 0.51 (0.38–0.69) <0.001
TVR by CABG 4 (0.3) 11 (1.0) 0.36 (0.11–1.12) 0.06
Any revascularization 97 (8.4) 141 (12.2) 0.67 (0.51–0.86) 0.002
Bleeding‡§
BARC 1–5 215 (18.1) 225 (19.1) 0.95 (0.78–1.14) 0.56
BARC 2–5 166 (13.9) 172 (14.7) 0.96 (0.77–1.18) 0.68
BARC 3–5 85 (7.2) 85 (7.3) 0.99 (0.73–1.34) 0.96
*  Percentages are Kaplan–Meier estimates at 390 days. TLR denotes target-lesion revascularization, and TVR target-vessel 
revascularization.
†  P<0.001 for noninferiority comparison (primary analysis).
‡  Subcategories of myocardial infarction, stent thrombosis, or bleeding are not mutually exclusive, because patients 
could have more than one subtype of these events during follow-up.
§  Bleeding was defined according to the Bleeding Academic Research Consortium (BARC) definitions. BARC type 0 indi-
cates no bleeding, and BARC type 5 indicates fatal bleeding.12
Table 2. Primary and Secondary End Points.*
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superiority). The time-to-event curves for the 
primary safety end point are shown in Fig. 2A.
At 390 days, the primary efficacy end point 
(clinically driven target-lesion revascularization) 
had occurred in 59 patients (5.1%) in the drug-
coated–stent group and in 113 patients (9.8%) in 
the bare-metal–stent group (estimated risk differ-
ence, −4.8 percentage points; 95% CI, −6.9 to −2.6; 
hazard ratio, 0.50; 95% CI, 0.37 to 0.69; P<0.001) 
(Table 2). The time-to-event curves for the pri-
mary efficacy end point are shown in Fig. 2B.
Additional Analyses
Significant differences between the two groups 
were also observed with respect to other revas-
cularization end points and with respect to 
myocardial infarction (Table 2, and Fig. S1 in 
the Supplementary Appendix). Among subtypes 
of myocardial infarction based on the third uni-
versal definition of myocardial infarction, type 1 
(spontaneous myocardial infarction) and type 4c 
(myocardial infarction related to in-stent reste-
nosis) occurred significantly less frequently in 
the drug-coated–stent group than in the bare-
metal–stent group (Table S3 in the Supplemen-
tary Appendix). The rates of bleeding according 
to BARC criteria were similar in the two groups 
(Table 2, and Fig. S1 in the Supplementary Ap-
pendix). Results in the as-treated analysis were 
similar to those in the intention-to-treat analysis 
(Table S4 in the Supplementary Appendix).
Prespecified subgroup comparisons for the 
primary efficacy and safety end points are 
shown in Fig. 3; a post hoc subgroup analysis 
based on an age cutoff of 75 years is shown in 
Table S5 in the Supplementary Appendix. These 
analyses show a consistent treatment effect 
across most subgroups. However, interaction 
testing suggested heterogeneity of treatment 
effect with regard to the primary safety end 
point according to whether or not the patient 
presented with an acute coronary syndrome. 
Heterogeneity of treatment effect with regard to 
the primary efficacy end point was suggested in 
subgroups defined according to the presence or 
absence of renal failure on admission, the score 
on the CRUSADE (Can Rapid Risk Stratification 
of Unstable Angina Patients Suppress Adverse 
Outcomes with Early Implementation of the 
American College of Cardiology/American Heart 
Association Guidelines) bleeding risk scale,8 and 
status with respect to anemia, transfusion, or 
bleeding leading to hospitalization.
Discussion
In the LEADERS FREE trial involving patients at 
high risk for bleeding who underwent PCI, the 
rate of the composite primary safety end point 
of cardiac death, myocardial infarction, or stent 
thrombosis was significantly lower with the 
BioFreedom polymer-free and carrier-free umi-
rolimus-coated stent than with a similar bare-
metal stent. This result was driven mainly by a 
Figure 2. Time-to-Event Curves for the Primary End Points.
Kaplan–Meier time-to-event curves show the cumulative percentage of 
 patients with the primary safety end point (a composite of cardiac death, 
myocardial infarction, or stent thrombosis) (Panel A) or the primary effi-
cacy end point (clinically driven target-lesion revascularization) (Panel B). 
The inset in each panel shows the same data on an enlarged y axis.
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lower rate of myocardial infarction. In addition, 
the rate of the primary efficacy end point of 
clinically driven target-lesion revascularization 
was significantly lower with the drug-coated 
stent than with the bare-metal stent.
The trial was designed with the intention of 
enrolling patients who were considered to be at 
high risk for bleeding or who were, for any rea-
son, considered not to be candidates for pro-
longed use of dual antiplatelet therapy. As ex-
pected in this high-risk population, despite the 
short course of dual antiplatelet therapy, the rate 
of bleeding was high (with 7.2% of patients 
meeting criteria for BARC types 3 to 5 bleeding) 
and was similar in the two groups. In contrast, 
the rate of major bleeding ranged from 0.6% to 
2.8% during the first year after PCI in trials that 
included patients at low-to-moderate risk who 
received dual antiplatelet therapy for longer du-
rations.13-15
It is notable that 64% of the trial participants 
were regarded as being at high risk for bleeding 
specifically because of age; many such patients 
might not be regarded as requiring a shortened 
course of dual antiplatelet therapy in routine 
clinical practice. We chose the age of 75 years to 
define a population at increased risk for bleed-
ing because this was a frequently used cutoff 
value in major trials of bleeding associated with 
antiplatelet treatment and in studies focusing on 
risk factors for bleeding after PCI.16-18
The rate of myocardial infarction was signifi-
cantly lower in the drug-coated–stent group 
than in the bare-metal–stent group. Spontane-
ous myocardial infarction (type 1) and myocar-
dial infarction related to in-stent restenosis (type 
4c), as categorized according to the third univer-
sal definition of myocardial infarction,9 oc-
curred significantly less frequently among pa-
tients with a drug-coated stent. Because routine 
angiography was not systematically performed, 
it is likely that many of the spontaneous myocar-
dial infarctions were also related to in-stent re-
stenosis, although this uncertainty does not af-
fect the comparison between treatment groups.
The rate of periprocedural myocardial infarc-
tion (type 4a) was low in both groups, which 
may be a consequence of the approach taken in 
our trial to detect such events. The protocol 
mandated at least one biomarker determination 
during a time window of 18 to 24 hours after 
PCI, or before discharge if this occurred earlier. 
We may have therefore underestimated the rate 
of periprocedural myocardial infarction, although 
this limitation applies equally to both treatment 
groups given the blinding of the trial.
Rates of definite or probable stent thrombo-
sis in this study were high, although they are 
similar to those reported in some “all-comer” 
trials of drug-eluting stents19-21 as well as in trials 
of triple therapy9 or in trials involving patients 
who were considered to be uncertain candidates 
for drug-eluting stents.22 The rate of stent throm-
bosis did not differ significantly between the 
two groups, and more than half the stent throm-
boses in both groups occurred during the first 
30 days, when patients were prescribed dual 
antiplatelet therapy. These high rates of stent 
thrombosis may be a consequence of the high 
risk of bleeding among the trial participants, 
because patients at the highest risk for bleeding 
are often also at the highest risk for stent throm-
bosis.23
Current European guidelines3 suggest the use 
of polymer-coated, new-generation drug-eluting 
stents with a 3-month course of dual antiplatelet 
therapy as an alternative option for PCI in pa-
tients at increased risk for bleeding, but they 
stress that this recommendation is based on 
only limited evidence. These guidelines were not 
available at the time of trial design, when the 
only reference treatment was a bare-metal stent 
with 1 month of dual antiplatelet therapy. Fur-
ther evaluation is warranted of the use of the 
polymer-free drug-coated stent in comparison 
with currently available drug-eluting stents with 
a shortened course of dual antiplatelet therapy in 
patients at increased risk for bleeding.
In summary, patients at high risk for bleed-
ing who underwent PCI received either a polymer-
free umirolimus-coated stent or a bare-metal 
stent, with a 1-month course of dual antiplatelet 
therapy. Use of the drug-coated stent, as com-
pared with the bare-metal stent, was associated 
with a lower rate of the composite primary 
safety end point of cardiac death, myocardial 
infarction, or stent thrombosis and a lower rate 
of the primary efficacy end point of clinically 
driven target-lesion revascularization.
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